Document Security Systems, Inc. (DSS) News
Filter DSS News Items
DSS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DSS News From Around the Web
Below are the latest news stories about DSS INC that investors may wish to consider to help them evaluate DSS as an investment opportunity.
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder ValueNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will begin |
AmericaFirst Funds Trust Announces Changes to Board of TrusteesNEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and Allan Siegel have resigned from their positions as independent directors. The Trust is pleased to announce the election of three new independent directors by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson and Mark Gronet. These individuals are seasoned senior investment executives who bring a |
DSS, Inc. Names Jason Grady as Interim Chief Executive OfficerNEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as Chief Operating Officer of DSS, Inc., brings over 25 years of extensive experience in executive leadership, business development, restructuring, and operations management across a variety of industries. He will succeed Frank D. Heuszel, who is exiting the company to transition to a leadership role wi |
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform. The Laetose™ technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, whi |